• Publications
  • Influence
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
EGF receptor (EGFR) inhibition is efficacious in cancer therapy, but initially sensitive tumors often develop resistance. In this study, we investigated the potential to overcome acquired resistanceExpand
  • 139
  • 8
  • PDF
The nuclear epidermal growth factor receptor signaling network and its role in cancer.
The epidermal growth factor receptor (EGFR) is a member of the EGFR family of receptor tyrosine kinases (RTKs). EGFR activation via ligand binding results in signaling through various pathwaysExpand
  • 181
  • 6
p27Kip1 Stabilization and G1 Arrest by 1,25-Dihydroxyvitamin D3 in Ovarian Cancer Cells Mediated through Down-regulation of Cyclin E/Cyclin-dependent Kinase 2 and Skp1-Cullin-F-box Protein/Skp2
p27Kip1 (p27) is a tumor suppressor whose stability is controlled by proteasome-mediated degradation, a process directed in part by cyclin-dependent kinase 2 (CDK2)-mediated phosphorylation of p27 atExpand
  • 124
  • 6
p53 modulates acquired resistance to EGFR inhibitors and radiation.
There is presently great interest in mechanisms of acquired resistance to epidermal growth factor receptor (EGFR) inhibitors that are now being used widely in the treatment of a variety of commonExpand
  • 89
  • 5
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux) in metastatic colorectal cancer (mCRC). This study sought to determine if KRAS mutant CRC lines could be sensitized toExpand
  • 105
  • 2
Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
BACKGROUND AND PURPOSE The aberrant expression of epidermal growth factor receptor (EGFR) has been linked to the etiology of head and neck squamous cell carcinoma (HNSCC). The first major phase IIIExpand
  • 58
  • 2
Yes and Lyn play a role in nuclear translocation of the Epidermal Growth Factor Receptor
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in human cancers. Cetuximab is an anti-EGFR antibody that has been approved for use in oncology. Previously weExpand
  • 59
  • 2
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for headExpand
  • 55
  • 2
Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089.
PURPOSE The poor response of advanced epithelial ovarian cancer to current treatments necessitates the development of alternative therapeutic strategies. Inhibition of cancer growth byExpand
  • 82
  • 1
  • PDF
PKCδ-mediated phosphorylation of BAG3 at Ser187 site induces epithelial−mesenchymal transition and enhances invasiveness in thyroid cancer FRO cells
Protein kinase C delta (PKCδ) is a serine (Ser)/threonine kinase, which regulates numerous cellular processes, including proliferation, differentiation, migration and apoptosis. In the current study,Expand
  • 30
  • 1